The European Society of Cardiology has recommended that evaluating serum cardiac biomarkers, such as Troponin-T (Trop-T) and NT-proBNP, both at baseline and during or after treatment, may serve as a valuable diagnostic tool in the detection of subclinical cancer therapy-related cardiac dysfunction (CTRCD) and in tailoring oncological therapies based on individual risk profiles​ (16). This evidence concerns the gene NPPB and cancer.